Metabolic Diseases

Disease

Related News

China's Regulatory Reforms Accelerate Biotech Innovation and Global Partnerships

China's regulatory reforms since 2015 have streamlined clinical trial and drug approval processes, accelerating development of advanced therapies like CAR-T and bispecific antibodies. These changes have boosted investor confidence and created opportunities for global pharmaceutical partnerships with Chinese biotech companies that have innovative pipelines but lack international marketing capabilities.

InSilico and Eli Lilly Announce $2.75 Billion AI Drug Discovery Partnership

InSilico Medicine and Eli Lilly have entered a major AI drug discovery collaboration potentially worth $2.75 billion, with Lilly gaining exclusive rights to develop preclinical oral therapies. InSilico will receive $115 million upfront plus milestone payments and royalties. The deal reflects increasing pharmaceutical industry adoption of AI platforms to accelerate drug development.

Related Clinical Trials

NCT ID Title Status Phase
NCT07576374

Specificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West Indies

NOT_YET_RECRUITING
NCT07547098

Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome

RECRUITING
NCT07534670

Early Pregnancy Lifestyle and Glucose Patterns: A Substudy of TOFFFY

NOT_YET_RECRUITING NA
NCT07356557

Evaluation of Therapeutic Adherence Among Patients Followed in the Department of Hereditary Metabolic Diseases at Necker Hospital

RECRUITING
NCT07343336

Landscape of Gout in French Polynesia.

RECRUITING
NCT07263269

Comparing Dumping Symptoms and Quality of Life 6 Months After Sleeve Gastrectomy With or Without Transit Bipartition in Adults With Obesity

ACTIVE_NOT_RECRUITING NA
NCT07215533

Effects of HIIT vs. TRE on Type 2 Diabetes Risk

RECRUITING NA
NCT07205510

Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)

RECRUITING
NCT06973408

The SWITCH Dietary and Behavioural Intervention Study

RECRUITING NA
NCT06968208

The Efficacy and Safety of Puerarin in Obesity Treatment

NOT_YET_RECRUITING PHASE2